Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Myeloma Multiple

Carmustine is a bicyclohexylnitrosourea (BCNU, Fig. 3) with broad spectrum of antineoplastic activity (e.g., lymphomas, multiple myeloma, sarcomas, brain tumors, gastrointestinal tumors, melanomas). At doses of 80-200 mg/m2 it is given i.v. at 6 week s intervals. [Pg.56]

Bendamustine is a useful antineoplastic drug for the treatment of non-Hodgkin s lymphomas, multiple myeloma and as a partner drug in the combination therapy of some solid tumors. The cross-resistance with other alkylating drugs is not complete. Myelosuppression and lymphocytopenia is its main dose-limiting toxicity. [Pg.57]

Liposomal encapsulation of DOX or DNR Preferred anthracycline delivery to the tumor Breast cancer, ovarian cancer, AIDS-related Kaposi s sarcoma, multiple myeloma (pegylated liposomal DOX). Breast cancer (uncoated liposomal DOX). AIDS-related Kaposi s sarcoma, acute mye-loblastic leukemia, multiple myeloma, non-Hodgkin s lymphomas (uncoated liposomal DNR)... [Pg.95]

Antineoplastic agents that cannot be grouped under subheadings 1-9 include miltefosine which is an alkylphosphocholine that is used to treat skin metastasis of breast cancer, and crispantase which breaks down asparagine to aspartic acid and ammonia. It is active against tumor cells that lack the enzyme asparaginase, such as acute lymphoblastic leukemia cells. Side effects include irritation of the skin in the case of miltefosine and anaphylactic reactions in the case of crispantase. Another recent development is the proteasome inhibitor bortezomib which is used to treat multiple myeloma. [Pg.156]

Bisphosphonates have been shown to be highly effective in osteoporosis, cancer bone metastasis, multiple myeloma, and Paget s disease of bone. While generally very well tolerated, these drugs do have potential adverse effects. Recently, the association of long-term high dose bisphosphonate treatment with osteonecrosis of the jaw has been described. This is a potentially serious side effect seen mostly in patients with multiple myeloma or... [Pg.281]

Proteasomal inhibition represents a novel strategy in cancer treatment and the small molecule Bortezomid (PS-341, Velcade ) has been approved for the treatment of refractory and relapsed multiple myeloma, a proliferative disease of plasma cells. Bortezomid inhibits an active site in a proteasome subunit and remarkably shows selective cytotoxicity to cancer cells. Although the underlying mechanisms are not completely understood bortezomid apparently induces a cell stress response in these tumor cells followed by caspase-dependent apoptosis. Whether bortezomid is beneficial for the treatment of other proliferative disease is currently being tested in clinical trials. [Pg.1266]

Lung (Fz9) Multiple myeloma Colorectal cancer Skin cancer Leukemia... [Pg.1320]

Creatinine clearance < 60 mL/min/1.73 m2 (stages III-V chronic kidney disease), diabetes mellitus (with renal insufficiency), hypertension, chronic heart failure, cirrhosis, nephrosis, age >75 yr, cholesterol emboli syndrome, multiple myeloma (questionable)... [Pg.155]

Nephrotic syndrome, multiple myeloma, Wilson s disease, and amyloidosis... [Pg.178]

Systemic lupus erythematosus, Sjogren s syndrome, multiple myeloma, obstructive uropathy, cirrhosis, and sickle cell disease... [Pg.178]

Any time an ABG is analyzed it is wise to concurrently inspect the serum chemistry values to calculate the anion gap. The body does not generate an anion gap to compensate for a primary disorder. As such, if the calculated anion gap exceeds 12 mEq/L (mmol/L) there is a primary metabolic acidosis regardless of the pH or the serum HC03 concentration. The anion gap may be artificially lowered by decreased serum albumin, multiple myeloma, lithium intoxication, or a profound increase in the serum potassium, calcium, or magnesium. [Pg.424]

Liposomal doxorubicin is an irritant, not a vesicant, and is dosed differently from doxorubicin, so clinicians need to be very careful when prescribing these two drugs. The pharmacokinetics of liposomal doxorubicin are best described by a two-compartment model, with a terminal half-life of 30 to 90 hours.20 Liposomal doxorubicin has shown significant activity in the treatment of breast and ovarian cancer, along with multiple myeloma and Kaposi s sarcoma. Side effects include mucositis, myelosuppression, alopecia, and palmar-plantar erythrodysesthesia. The liposomal doxorubicin may be less cardiotoxic than doxorubicin. [Pg.1289]

Lenalidomide was approved recently for the indication of myelodysplastic syndrome where the 5q deletion is present. Since lenalidomide is an analog of thalidomide, all the same precautions must be taken to prevent phocomelia. The time to maximum lenalidomide concentrations occurs 0.5 to 4 hours after the dose. The terminal half-life ranges from 3 to 9 hours. Approximately 65% of lenalidomide is eliminated unchanged in the urine, with clearance exceeding the glomerular filtration rate. To date, no pharmacokinetic studies have been done in patients with renal dysfunction. Lenalidomide is used in the treatment of myelodysplastic syndrome and multiple myeloma. Other side effects are neutropenia, thrombocytopenia, deep vein thrombosis, and pulmonary embolus. [Pg.1293]

Vincristine (VCR, Oncovin) ALL HD NHL multiple myeloma breast cancer SCLC, KS brain tumors soft tissue sarcomas osteosarcomas neuroblastoma Wilms tumor... [Pg.1409]

Discuss treatment options available for multiple myeloma. ... [Pg.1415]

Multiple myeloma is a malignancy of plasma cells that is characterized by an abnormal production of a monoclonal protein. Features of the disease include bone lesions, anemia, and... [Pg.1420]


See other pages where Myeloma Multiple is mentioned: [Pg.437]    [Pg.437]    [Pg.244]    [Pg.54]    [Pg.55]    [Pg.56]    [Pg.86]    [Pg.93]    [Pg.644]    [Pg.644]    [Pg.584]    [Pg.584]    [Pg.78]    [Pg.590]    [Pg.595]    [Pg.27]    [Pg.58]    [Pg.59]    [Pg.103]    [Pg.164]    [Pg.362]    [Pg.869]    [Pg.1060]    [Pg.1287]    [Pg.1289]    [Pg.1293]    [Pg.1415]    [Pg.1415]    [Pg.1417]    [Pg.1419]    [Pg.1420]    [Pg.1421]    [Pg.1421]    [Pg.1421]   
See also in sourсe #XX -- [ Pg.595 ]

See also in sourсe #XX -- [ Pg.1420 , Pg.1421 , Pg.1422 ]

See also in sourсe #XX -- [ Pg.447 ]

See also in sourсe #XX -- [ Pg.447 ]

See also in sourсe #XX -- [ Pg.1836 ]

See also in sourсe #XX -- [ Pg.99 , Pg.114 ]

See also in sourсe #XX -- [ Pg.237 ]

See also in sourсe #XX -- [ Pg.375 ]

See also in sourсe #XX -- [ Pg.133 ]

See also in sourсe #XX -- [ Pg.818 ]

See also in sourсe #XX -- [ Pg.141 , Pg.148 ]

See also in sourсe #XX -- [ Pg.609 ]

See also in sourсe #XX -- [ Pg.643 ]

See also in sourсe #XX -- [ Pg.536 ]

See also in sourсe #XX -- [ Pg.573 , Pg.574 , Pg.1717 ]

See also in sourсe #XX -- [ Pg.554 , Pg.953 ]

See also in sourсe #XX -- [ Pg.86 ]

See also in sourсe #XX -- [ Pg.2286 ]

See also in sourсe #XX -- [ Pg.8 , Pg.150 ]

See also in sourсe #XX -- [ Pg.261 , Pg.266 ]

See also in sourсe #XX -- [ Pg.459 ]

See also in sourсe #XX -- [ Pg.984 ]

See also in sourсe #XX -- [ Pg.200 ]

See also in sourсe #XX -- [ Pg.107 ]

See also in sourсe #XX -- [ Pg.54 ]

See also in sourсe #XX -- [ Pg.791 ]

See also in sourсe #XX -- [ Pg.240 ]

See also in sourсe #XX -- [ Pg.254 ]

See also in sourсe #XX -- [ Pg.197 ]

See also in sourсe #XX -- [ Pg.704 ]

See also in sourсe #XX -- [ Pg.488 ]

See also in sourсe #XX -- [ Pg.99 ]

See also in sourсe #XX -- [ Pg.172 , Pg.602 ]

See also in sourсe #XX -- [ Pg.463 ]

See also in sourсe #XX -- [ Pg.171 ]

See also in sourсe #XX -- [ Pg.240 ]




SEARCH



Bone disease multiple myeloma

Immunoglobulin multiple myeloma and

Lymphohematopoietic study of workers exposed to benzene including multiple myeloma, lymphoma and chronic lymphatic leukemia

Multiple myeloma Cancer

Multiple myeloma NSAIDs

Multiple myeloma bisphosphonates

Multiple myeloma bortezomib

Multiple myeloma case study

Multiple myeloma chemotherapy

Multiple myeloma clinical presentation

Multiple myeloma corticosteroids

Multiple myeloma diagnosis

Multiple myeloma electrophoretic patterns

Multiple myeloma epidemiology

Multiple myeloma hypercalcemia

Multiple myeloma lenalidomide

Multiple myeloma progression

Multiple myeloma protein formation

Multiple myeloma proteins

Multiple myeloma renal failure

Multiple myeloma serum proteins

Multiple myeloma thalidomide

Multiple myeloma treatment

Myeloma

Renal failure in multiple myeloma

© 2024 chempedia.info